<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Binimetinib: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Binimetinib: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Binimetinib: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="118397" href="/d/html/118397.html" rel="external">see "Binimetinib: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F51646074"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Mektovi</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F56263112"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Mektovi</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F51619847"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent, MEK Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F51675689"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety</b>
<b>:</b> Binimetinib is associated with a moderate or high emetic potential; antiemetics may be recommended to prevent nausea and vomiting.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="16eddff6-4da9-42f2-9cbd-650df0be3bb0">Melanoma, unresectable or metastatic, with <i>BRAF V600E</i> or <i>BRAF V600K</i> mutation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Melanoma, unresectable or metastatic, with <i>BRAF</i> V600E or <i>BRAF</i> V600K mutation: Note:</b> Confirm <i>BRAF</i> V600E or V600K mutation status in tumor specimens prior to initiation.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 45 mg twice daily (in combination with encorafenib); continue until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37506329','lexi-content-ref-29573941','lexi-content-ref-35862871']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37506329','lexi-content-ref-29573941','lexi-content-ref-35862871'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3b77c027-d3bb-46a0-90a6-0ba437a8a192">Melanoma, unresectable or metastatic, with NRAS mutation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Melanoma, unresectable or metastatic, with <i>NRAS</i> mutation (off-label use): Oral:</b> 45 mg twice daily as a single agent; continue until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28284557']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28284557'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="68cd2181-bf4a-45fe-8534-a9ced877f833">Non-small cell lung cancer, metastatic, with <i>BRAF</i> V600E mutation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Non-small cell lung cancer, metastatic, with <i>BRAF</i> V600E mutation: </b>
<b>Note:</b> Confirm <i>BRAF</i> V600E mutation status in tumor or plasma specimens prior to initiation; if no mutation detected in plasma specimens, then test tumor tissue.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 45 mg twice daily (in combination with encorafenib); continue until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37270692']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37270692'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<i>Missed doses:</i> Do not administer a missed dose if &lt;6 hours until the next dose. Do not administer an additional dose if vomiting occurs after binimetinib administration; resume with the next scheduled dose.</p></div>
<div class="block dora drugH1Div" id="F51675691"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, kidney impairment does not have any clinically relevant effect on binimetinib exposure. No dosage adjustment is necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30942181']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30942181'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Hemodialysis: Not likely dialyzed due to extensive protein binding (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>). No need for dosage adjustment is expected (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30942181']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30942181'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F51675692"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatic impairment prior to treatment initiation:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Mild impairment (total bilirubin &gt;1 to ≤1.5 times ULN and any AST or total bilirubin ≤ ULN and AST &gt; ULN): No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">Moderate (total bilirubin &gt;1.5 to ≤3 times ULN and any AST) to severe (total bilirubin &gt;3 times ULN and any AST) impairment: 30 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute hepatotoxicity during treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Grade 2 AST or ALT elevations: Maintain binimetinib dose; if no improvement within 2 weeks, withhold binimetinib until improvement to grade 0 or 1 or to pretreatment/baseline levels and then resume at the same dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Grade 3 AST or ALT elevation: For the first occurrence of grade 3 AST or ALT elevations, withhold binimetinib for up to 4 weeks; if improves to grade 0 or 1 or to pretreatment/baseline level, resume binimetinib at a reduced dose. If no improvement, permanently discontinue binimetinib. For recurrent grade 3 toxicity, consider permanently discontinuing binimetinib.</p>
<p style="text-indent:-2em;margin-left:4em;">Grade 4 AST or ALT elevation: For the first occurrence of grade 4 AST or ALT elevations, permanently discontinue binimetinib <b>or</b> withhold binimetinib therapy for up to 4 weeks; if improves to grade 0 or 1, then resume binimetinib at a reduced dose. If no improvement, permanently discontinue binimetinib. For recurrent grade 4 toxicity, permanently discontinue binimetinib.</p></div>
<div class="block dot drugH1Div" id="F51675693"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> If binimetinib is withheld, reduce encorafenib dose until binimetinib is resumed; refer to encorafenib monograph for recommended encorafenib dose reductions. If encorafenib is permanently discontinued, discontinue binimetinib.</p>
<p style="text-indent:-2em;margin-left:2em;">When used in combination with encorafenib, binimetinib dosage modification is not recommended for palmar plantar erythrodysesthesia syndrome (PPES), non-cutaneous RAS mutation-positive malignancies, and QTc prolongation.</p>
<table border="1" frame="border" rules="all">
<caption style="text-align:left;">
<b>Binimetinib Dosage Reduction Schedule</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:center;">
<b>Dosage reduction levels</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:center;">
<b>Dosage and schedule</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:center;">Initial (usual) dosage</p></td>
<td align="left">
<p style="text-indent:0em;text-align:center;">45 mg twice daily</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:center;">First dosage reduction</p></td>
<td align="left">
<p style="text-indent:0em;text-align:center;">30 mg twice daily</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:center;">Subsequent modification (if unable to tolerate 30 mg twice daily)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:center;">Permanently discontinue binimetinib.</p></td></tr></tbody></table>
<table border="1" frame="border" rules="all">
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left" colspan="3">
<p style="text-indent:0em;text-align:center;">
<b>Recommended Binimetinib Dosage Modifications for Adverse Reactions</b></p></th></tr></thead>
<tfoot valign="top">
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;">
<sup>a</sup> LVEF = left ventricular ejection fraction; DVT = deep vein thrombosis; PE = pulmonary embolism.</p></td></tr></tfoot>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">
<b>Adverse reaction</b></p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">
<b>Severity</b></p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">
<b>Binimetinib dosage modification</b></p></td></tr>
<tr>
<td align="left" rowspan="2">
<p style="text-indent:0em;text-align:left;">
<b>Cardiotoxicity</b></p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Asymptomatic, absolute LVEF<sup>a</sup> decrease of &gt;10% from baseline and also below LLN</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold binimetinib for up to 4 weeks and evaluate LVEF every 2 weeks.</p>
<p style="text-indent:0em;text-align:left;">
<i>LVEF is ≥ LLN <b>and</b> absolute decrease from baseline is ≤10% <b>and</b> patient is asymptomatic</i>: Resume binimetinib at reduced dose.</p>
<p style="text-indent:0em;text-align:left;">
<i>LVEF does not recover within 4 weeks</i>: Permanently discontinue binimetinib.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Symptomatic heart failure or absolute decrease in LVEF of &gt;20% from baseline and also below LLN</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Permanently discontinue binimetinib.</p></td></tr>
<tr>
<td align="left" rowspan="3">
<p style="text-indent:0em;text-align:left;">
<b>Dermatologic toxicity</b></p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 2</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">
<i>No improvement within 2 weeks</i>: Withhold binimetinib until improved to grade 0 or 1; resume at same dose (if first occurrence) or reduced dose (if recurrent).</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 3</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold binimetinib until improved to grade 0 or 1; resume at same dose (if first occurrence) or reduced dose (if recurrent).</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 4</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Permanently discontinue binimetinib.</p></td></tr>
<tr>
<td align="left" rowspan="5">
<p style="text-indent:0em;text-align:left;">
<b>Ocular toxicity</b></p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Retinal vein occlusion (any grade)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Permanently discontinue binimetinib.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Symptomatic serous retinopathy/retinal pigment epithelial detachment</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold binimetinib for up to 10 days.</p>
<p style="text-indent:0em;text-align:left;">
<i>Improvement within 10 days of interruption and asymptomatic</i>: Resume binimetinib at same dose.</p>
<p style="text-indent:0em;text-align:left;">
<i>No improvement within 10 days of interruption</i>: Resume binimetinib at reduced dose or permanently discontinue.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Uveitis (grade 1 to 2)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">
<i>If no response to specific ocular therapy</i>: Withhold binimetinib for up to 6 weeks.</p>
<p style="text-indent:0em;text-align:left;">
<i>Improvement within 6 weeks of interruption</i>: Resume binimetinib at same or reduced dose.</p>
<p style="text-indent:0em;text-align:left;">
<i>No improvement within 6 weeks of interruption</i>: Permanently discontinue binimetinib.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Uveitis (grade 3)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold binimetinib for up to 6 weeks.</p>
<p style="text-indent:0em;text-align:left;">
<i>Improvement within 6 weeks of interruption</i>: Resume binimetinib at same or reduced dose.</p>
<p style="text-indent:0em;text-align:left;">
<i>No improvement within 6 weeks of interruption</i>: Permanently discontinue binimetinib.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Uveitis (grade 4)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Permanently discontinue binimetinib.</p></td></tr>
<tr>
<td align="left" rowspan="2">
<p style="text-indent:0em;text-align:left;">
<b>Pulmonary toxicity</b></p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Interstitial lung disease (grade 2)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold binimetinib for up to 4 weeks.</p>
<p style="text-indent:0em;text-align:left;">
<i>Improvement to grade 0 or 1 within 4 weeks of interruption</i>: Resume binimetinib at reduced dose.</p>
<p style="text-indent:0em;text-align:left;">
<i>No improvement within 4 weeks of interruption</i>: Permanently discontinue binimetinib.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Interstitial lung disease (grade 3 or 4)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Permanently discontinue binimetinib.</p></td></tr>
<tr>
<td align="left" rowspan="2">
<p style="text-indent:0em;text-align:left;">
<b>Rhabdomyolysis or CPK elevation</b></p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 4 asymptomatic CPK elevation</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold binimetinib for up to 4 weeks.</p>
<p style="text-indent:0em;text-align:left;">
<i>Improvement to grade 0 or 1 within 4 weeks of interruption</i>: Resume binimetinib at reduced dose.</p>
<p style="text-indent:0em;text-align:left;">
<i>No improvement within 4 weeks of interruption</i>: Permanently discontinue binimetinib.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Any grade CPK elevation with symptoms or with kidney impairment</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold binimetinib for up to 4 weeks.</p>
<p style="text-indent:0em;text-align:left;">
<i>Improvement to grade 0 or 1 within 4 weeks of interruption</i>: Resume binimetinib at reduced dose.</p>
<p style="text-indent:0em;text-align:left;">
<i>No improvement within 4 weeks of interruption</i>: Permanently discontinue binimetinib.</p></td></tr>
<tr>
<td align="left" rowspan="2">
<p style="text-indent:0em;text-align:left;">
<b>Thromboembolism</b></p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Uncomplicated DVT<sup>a</sup> or PE<sup>a</sup></p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold binimetinib.</p>
<p style="text-indent:0em;text-align:left;">
<i>Improvement to grade 0 to 1</i>: Resume binimetinib at reduced dose.</p>
<p style="text-indent:0em;text-align:left;">
<i>No improvement</i>: Permanently discontinue binimetinib.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Life-threatening PE</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Permanently discontinue binimetinib.</p></td></tr>
<tr>
<td align="left" rowspan="4">
<p style="text-indent:0em;text-align:left;">
<b>Other treatment-related adverse reaction (including hemorrhage)</b></p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 2 (recurrent) or grade 3 (first occurrence)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold binimetinib for up to 4 weeks.</p>
<p style="text-indent:0em;text-align:left;">
<i>Improvement to grade 0 or 1 or pretreatment/baseline levels within 4 weeks of interruption</i>: Resume binimetinib at reduced dose.</p>
<p style="text-indent:0em;text-align:left;">
<i>No improvement within 4 weeks of interruption</i>: Permanently discontinue binimetinib.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 4 (first occurrence)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Permanently discontinue binimetinib <b>or</b> withhold binimetinib for up to 4 weeks.</p>
<p style="text-indent:0em;text-align:left;">
<i>Improvement to grade 0 or 1 or pretreatment/baseline levels within 4 weeks of interruption</i>: Resume binimetinib at reduced dose.</p>
<p style="text-indent:0em;text-align:left;">
<i>No improvement within 4 weeks of interruption</i>: Permanently discontinue binimetinib.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 3 (recurrent)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Consider permanently discontinuing binimetinib.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 4 (recurrent)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Permanently discontinue binimetinib.</p></td></tr></tbody></table></div>
<div class="block doe drugH1Div" id="F51675690"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F51637332"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Percentages reported as part of combination chemotherapy regimens in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cardiomyopathy (absolute decreased left ventricular ejection fraction ≥10% below baseline: 7% to 11%), edema (23%), hypertension (10% to 11%), peripheral edema (13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia (12%), pruritus (16%), skin rash (22% to 27%), xeroderma (13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyperglycemia (48%), hyperkalemia (31%), hypoalbuminemia (32%), hypocalcemia (12%), hyponatremia (18% to 26%), weight gain (11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (28% to 32%), constipation (22% to 27%), decreased appetite (14%), diarrhea (36% to 52%; grades 3/4: 3% to 7%), increased serum amylase (22%), increased serum lipase (40%), nausea (41% to 58%; grades 3/4: 2% to 3%), vomiting (30% to 37%; grades 3/4: 1% to 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (36% to 47%; grades 3/4: 4% to 11%), hemorrhage (12% to 19%; grades 3/4: 3% to 4%), leukopenia (12% to 13%), lymphocytopenia (13% to 24%; grades 3/4: 2% to 6%), neutropenia (12% to 13%; grades 3/4: 1% to 3%), thrombocytopenia (20%; grades 3/4: 1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased gamma-glutamyl transferase (45%), increased serum alanine aminotransferase (29% to 34%), increased serum alkaline phosphatase (21% to 31%), increased serum aspartate aminotransferase (27% to 31%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (15% to 17%), fatigue (43% to 61%), headache (11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Increased creatine phosphokinase in blood specimen (41% to 58%), musculoskeletal pain (48%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Retinopathy (serous: 20%, including macular edema [6%], retinal detachment [2% to 8%]), visual impairment (20% to 29%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased serum creatinine (91% to 93%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (26%), dyspnea (27%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (18% to 22%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Pulmonary embolism (1% to 3%), venous thromboembolism (6% to 7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Cutaneous papilloma (2%), erythema of skin, hyperkeratosis, squamous cell carcinoma of skin (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Anal hemorrhage (2%), colitis, dysgeusia, hematochezia (3%), hemorrhoidal bleeding (1%), pancreatitis, rectal hemorrhage (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Facial paresis, insomnia (10%), peripheral neuropathy</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Panniculitis</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Uveitis (1% to 4%, including iridocyclitis, iritis)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Hemothorax (2%), pneumonitis (1%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Ophthalmic: Retinal vein occlusion</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Intracranial hemorrhage</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute kidney injury</p></div>
<div class="block coi drugH1Div" id="F51618275"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">There are no contraindications listed in the manufacturer's labeling.</p></div>
<div class="block war drugH1Div" id="F51675665"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiotoxicity: Cardiomyopathy (manifesting as left ventricular dysfunction associated with symptomatic or asymptomatic ejection fraction decreases) has been reported in patients who received the combination of binimetinib and encorafenib. A decrease in left ventricular ejection fraction (LVEF) below the institutional LLN with an absolute decrease in LVEF ≥10% below baseline (detected by echocardiography or MUGA) has occurred. Grade 3 left ventricular dysfunction has been reported. The median time to first occurrence of any grade left ventricular dysfunction was 3.6 months (range: up to 21 months). Cardiomyopathy resolved in a majority of patients. Safety has not been established in patients with a baseline ejection fraction that is either &lt;50% or below the institutional LLN.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hemorrhage: Hemorrhage may occur with the combination of binimetinib and encorafenib, including ≥ grade 3 hemorrhage. The most frequent hemorrhagic events were gastrointestinal in nature, including rectal/anal hemorrhage, hematochezia, hemorrhoidal hemorrhage, and hemothorax. Fatal intracranial hemorrhage (may occur in the setting of new or progressive brain metastases) was also reported.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatotoxicity: Hepatotoxicity may occur with the combination of binimetinib and encorafenib; grade 3 or 4 elevations in ALT, AST, and/or alkaline phosphatase have been reported, although grade 3 or 4 total bilirubin elevations were not reported.</p>
<p style="text-indent:-2em;margin-left:4em;">• Malignancy: New primary malignancies (cutaneous and noncutaneous) may occur. Cutaneous squamous cell carcinoma and skin papilloma have been observed in a small percentage of patients who received the combination of binimetinib and encorafenib.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ocular toxicity: Serous retinopathy (including retinal detachment and macular edema) has occurred with the combination of binimetinib and encorafenib, Symptomatic serous retinopathy has been reported, although blindness did not occur. In clinical studies, some patients required treatment interruption or dose reduction due to serous retinopathy, although discontinuation was not required. The median time to onset of the first serous retinopathy event (all grades) was 1.2 months (range: up to 17.5 months). Retinal vein occlusion (RVO) is a known (class-related) adverse reaction of MEK inhibitors and may occur with the combination of binimetinib and encorafenib. The safety of binimetinib has not been established in patients with a history of RVO or current risk factors for RVO including uncontrolled glaucoma or a history of hyperviscosity or hypercoagulability syndromes. Uveitis, including iritis and iridocyclitis, has been reported in patients treated with the combination of binimetinib and encorafenib.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pulmonary toxicity: Cases of interstitial lung disease, including pneumonitis, developed in patients receiving the combination of binimetinib and encorafenib.</p>
<p style="text-indent:-2em;margin-left:4em;">• Rhabdomyolysis: Rhabdomyolysis may occur with the combination of binimetinib and encorafenib; CPK elevations may commonly occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thromboembolism: Venous thromboembolism, including pulmonary embolism, has occurred in patients receiving binimetinib in combination with encorafenib.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Combination therapy with encorafenib: Additional toxicities may occur when used in combination with encorafenib (<i>BRAF</i> inhibitor).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Prior to initiating therapy, confirm <i>BRAF</i> V600E or <i>BRAF</i> V600K mutation status with an approved test. Test tumor specimens for melanoma and tumor or plasma specimens for non-small cell lung cancer (NSCLC); if no mutation detected in plasma specimens, then test tumor tissue (NSCLC only). Information on approved tests for detection of <i>BRAF</i> V600 mutations is available at <a href="/external-redirect?target_url=http%3A%2F%2Fwww.fda.gov%2Fcompaniondiagnostics&amp;token=SHauxSdf9qNc6lLK16E8IFPiEHUnQ%2FrX%2FFBRnAtp%2BYOOMBGgh36vrA79ff4L%2FMZW&amp;TOPIC_ID=118324" target="_blank">http://www.fda.gov/companiondiagnostics</a>.</p></div>
<div class="block foc drugH1Div" id="F51646075"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Mektovi: 15 mg</p></div>
<div class="block geq drugH1Div" id="F51646073"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F51722114"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Mektovi Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">15 mg (per each): $104.05</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F56263113"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Mektovi: 15 mg</p></div>
<div class="block accres drugH1Div" id="F51675593"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:0em;display:inline">Binimetinib is available through specialty pharmacies and various specialty institutions or accounts. Examples from the manufacturer may be found at https://www.braftovimektovi.com/hcp.</p></div>
<div class="block adm drugH1Div" id="F51675695"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Administer twice a day (~12 hours apart) with or without food. Binimetinib is associated with a moderate or high emetic potential; antiemetics may be recommended to prevent nausea and vomiting.</p></div>
<div class="block meg drugH1Div" id="F58831072"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:-2em;margin-left:4em;">Mekoovi: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F210498s009lbl.pdf%23page%3D20&amp;token=TiTHx19%2ByTjyMKleL%2Bv%2FnEfs31CgrnvgDjMWFvNkstlg1iw6QEsh2%2FQlLA06Mu5NQfzP%2FU3rRW8awQNcCmekTqrHxi0a1FMtis0fO6Z0%2FoHi7M2BAiWSiy9X9WCgtBnx&amp;TOPIC_ID=118324" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/210498s009lbl.pdf#page=20</a></p></div>
<div class="block use drugH1Div" id="F51618274"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Melanoma, unresectable or metastatic, with <i>BRAF</i> V600E or <i>BRAF</i> V600K mutation:</b> Treatment of unresectable or metastatic melanoma with a <i>BRAF</i> V600E or V600K mutation (in combination with encorafenib). Select patients for therapy based on the presence of a <i>BRAF</i> V600E or <i>BRAF</i> V600K mutation in tumor specimens as detected by an approved test.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Non-small cell lung cancer, metastatic, with <i>BRAF</i> V600E mutation: </b>Treatment of metastatic non-small cell lung cancer (NSCLC) with a <i>BRAF</i> V600E mutation (in combination with encorafenib) in adults. Select patients for therapy based on the presence of a <i>BRAF</i> V600E mutation in tumor or plasma specimens as detected by an approved test.</p></div>
<div class="block off-label drugH1Div" id="F58731172"><span class="drugH1">Use: Off-Label: Adult</span><p>Melanoma, unresectable or metastatic, with NRAS mutation</p></div>
<div class="block mst drugH1Div" id="F51675591"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Binimetinib may be confused with alectinib, bosutinib, brigatinib, cobimetinib, encorafenib, neratinib, selumetinib, trametinib.</p>
<p style="text-indent:-2em;margin-left:4em;">Mektovi may be confused with Mekinist.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F51636184"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of BCRP/ABCG2, CYP1A2 (minor), CYP2C19 (minor), P-glycoprotein/ABCB1 (minor), UGT1A1; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F51636181"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Mitapivat: May decrease the serum concentration of UGT1A1 Substrates.<i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F51675663"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Verify pregnancy status prior to initiating binimetinib therapy in patients who could become pregnant. Patients who could become pregnant should use a highly effective contraceptive during therapy and for 30 days after the last binimetinib dose.</p></div>
<div class="block pri drugH1Div" id="F51675662"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on its mechanism of action and on findings in animal reproduction studies, in utero exposure to binimetinib may cause fetal harm.</p></div>
<div class="block brc drugH1Div" id="F51675664"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if binimetinib is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended by the manufacturer during treatment and for 3 days after the last binimetinib dose.</p></div>
<div class="block mop drugH1Div" id="F51675697"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>BRAF</i> mutation status: <i>BRAF</i> V600K or V600E mutation status in tumor specimens prior to treatment in melanoma. <i>BRAF</i> V600E mutation status in tumor or plasma specimens prior to treatment for non-small cell lung cancer (NSCLC); if no mutation detected in plasma specimens, then test tumor tissue.</p>
<p style="text-indent:-2em;margin-left:2em;">Monitor LFTs prior to treatment initiation, monthly during treatment, and as clinically indicated; monitor CPK and creatinine levels prior to treatment initiation, periodically during treatment, and as clinically indicated. Verify pregnancy status prior to treatment initiation in patients who could become pregnant. Assess ejection fraction (by echocardiogram or MUGA scan) prior to treatment initiation, one month after initiation, and then every 2 to 3 months during treatment; monitor closely in patients with cardiovascular risk factors. Evaluate visual symptoms at each visit; perform an ophthalmologic examination at regular intervals and for new or worsening visual disturbances (and to follow new or persistent ophthalmologic findings); perform ophthalmologic evaluation for patient-reported acute vision loss or other visual disturbance within 24 hours. Monitor for signs/symptoms of dermatologic toxicity, hemorrhage, interstitial lung disease (including new or progressive unexplained pulmonary symptoms/findings), new cutaneous or noncutaneous malignancy (prior to initiation of treatment, during treatment, and after discontinuation), ocular toxicity, rhabdomyolysis, and thromboembolism. Monitor adherence.</p>
<p style="text-indent:-2em;margin-left:2em;">The American Society of Clinical Oncology hepatitis B virus (HBV) screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends HBV screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up.</p>
<p style="text-indent:-2em;margin-left:2em;">Cardiovascular monitoring specifics: Comprehensive assessment prior to treatment including a history and physical examination, screening for cardiovascular disease risk factors such as hypertension, diabetes, dyslipidemia, obesity, and smoking (ASCO [Armenian 2017]). Assess BP at baseline and each clinical visit (as well as outpatient monitoring weekly for initial 3 months, then monthly thereafter), obtain a baseline echocardiography in high- and very-high risk patients scheduled to receive <i>BRAF</i>-MEK inhibitor combination therapy (consider repeating every 4 months during the first year); consider echocardiography in low- and moderate-risk patients scheduled to receive <i>BRAF</i>-MEK inhibitor combination therapy (ESC [Lyon 2022]).</p></div>
<div class="block pha drugH1Div" id="F51675672"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Binimetinib reversibly inhibits mitogen-activated extracellular kinase (MEK) 1 and 2 activation and kinase activity. MEK proteins are upstream regulators of the extracellular signal-related kinase (ERK) pathway. Binimetinib inhibits ERK phosphorylation and viability and MEK-dependent phosphorylation of the protein kinase B-raf (<i>BRAF</i>) mutant cell lines. In animal models, the combination also delayed the emergence of resistance in <i>BRAF</i> V600E mutant melanoma cells compared to either drug alone. In <i>BRAF</i> mutant non-small cell lung cancer animal models, after dosing cessation, increased tumor growth delays were also observed with the combination (compared to either drug alone).</p></div>
<div class="block phk drugH1Div" id="F51675673"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 92 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 97%; to human plasma proteins.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic; primarily via UGT1A1 glucuronidation; also via N-dealkylation, amide hydrolysis, and loss of side-chain ethane-diol. CYP1A2 and CYP2C19 contribute to the formation of the active metabolite M3.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: ≥50%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 3.5 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: 1.6 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces (62%; 32% as unchanged drug); urine (31%; 6.5% as unchanged drug).</p>
<p style="text-indent:-2em;margin-left:4em;">Clearance: 20.2 L/hour.</p></div>
<div class="block phksp drugH1Div" id="F51675682"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">Hepatic function impairment: A 2-fold increase in AUC was observed in subjects with moderate hepatic impairment (total bilirubin &gt;1.5 and ≤3 × ULN and any AST) or severe impairment (total bilirubin levels &gt;3 × ULN and any AST), compared to subjects with normal hepatic function.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F52765630"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Mektovi</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Mektovi</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Mektovi</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Mektovi</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Mektovi</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Mektovi</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Mektovi</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Mektovi</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Mektovi</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Mektovi</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Mektovi</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Mektovi</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Mektovi</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Mektovi</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Mektovi</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Mektovi</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Mektovi</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Mektovi</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Mektovi</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Mektovi</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Mektovi</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Mektovi</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Mektovi</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Mektovi</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-27918725">
<a name="27918725"></a>Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. <i>J Clin Oncol.</i> 2017;35(8):893-911. doi:10.1200/JCO.2016.70.5400<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/binimetinib-drug-information/abstract-text/27918725/pubmed" id="27918725" target="_blank">27918725</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37506329">
<a name="37506329"></a>Ascierto PA, Dummer R, Gogas HJ, et al. Contribution of MEK inhibition to BRAF/MEK inhibitor combination treatment of <i>BRAF</i>-mutant melanoma: part 2 of the randomized, open-label, phase III COLUMBUS trial. <i>J Clin Oncol</i>. 2023;41(29):4621-4631. doi:10.1200/JCO.22.02322<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/binimetinib-drug-information/abstract-text/37506329/pubmed" id="37506329" target="_blank">37506329</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29573941">
<a name="29573941"></a>Dummer R, Ascierto PA, Gogas HJ, et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicenter, open-label, randomized phase 3 trial.<i> Lancet Oncol.</i> 2018;19(5):603-615. doi:10.1016/S1470-2045(18)30142-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/binimetinib-drug-information/abstract-text/29573941/pubmed" id="29573941" target="_blank">29573941</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35862871">
<a name="35862871"></a>Dummer R, Flaherty KT, Robert C, et al. COLUMBUS 5-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with <i>BRAF</i> V600-mutant melanoma. <i>J Clin Oncol</i>. 2022;40(36):4178-4188. doi:10.1200/JCO.21.02659<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/binimetinib-drug-information/abstract-text/35862871/pubmed" id="35862871" target="_blank">35862871</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28284557">
<a name="28284557"></a>Dummer R, Schadendorf D, Ascierto PA, et al. Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncol</i>. 2017;18(4):435-445. doi:10.1016/S1470-2045(17)30180-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/binimetinib-drug-information/abstract-text/28284557/pubmed" id="28284557" target="_blank">28284557</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/binimetinib-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30942181">
<a name="30942181"></a>Krens SD, Lassche G, Jansman FGA, et al. Dose recommendations for anticancer drugs in patients with renal or hepatic impairment. <i>Lancet Oncol</i>. 2019;20(4):e200-e207. doi:10.1016/S1470-2045(19)30145-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/binimetinib-drug-information/abstract-text/30942181/pubmed" id="30942181" target="_blank">30942181</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36017568">
<a name="36017568"></a>Lyon AR, López-Fernández T, Couch LS, et al; ESC Scientific Document Group. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). <i>Eur Heart J.</i> 2022;43(41):4229-4361. doi:10.1093/eurheartj/ehac244<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/binimetinib-drug-information/abstract-text/36017568/pubmed" id="36017568" target="_blank">36017568</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Mektovi (binimetinib) [prescribing information]. Boulder, CO: Array BioPharma Inc; October 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37270692">
<a name="37270692"></a>Riely GJ, Smit EF, Ahn MJ, et al. Phase II, open-label study of encorafenib plus binimetinib in patients with <i>BRAF</i>
<sup>V600</sup>-mutant metastatic non-small-cell lung cancer. <i>J Clin Oncol</i>. 2023;41(21):3700-3711. doi:10.1200/JCO.23.00774<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/binimetinib-drug-information/abstract-text/37270692/pubmed" id="37270692" target="_blank">37270692</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33503393">
<a name="33503393"></a>Tabernero J, Grothey A, Van Cutsem E, et al. Encorafenib plus cetuximab as a new standard of care for previously treated BRAFV600E-mutant metastatic colorectal cancer: updated survival results and subgroup analyses from the BEACON study. <i>J Clin Oncol. </i>2021;39(4):273-284. doi:10.1200/JCO.20.02088<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/binimetinib-drug-information/abstract-text/33503393/pubmed" id="33503393" target="_blank">33503393</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30892987">
<a name="30892987"></a>Van Cutsem E, Huijberts S, Grothey A, et al. Binimetinib, encorafenib, and cetuximab triplet therapy for patients with BRAF V600E-mutant metastatic colorectal cancer: safety lead-in results from the phase III BEACON Colorectal Cancer Study. <i>J Clin Oncol</i>. 2019;37(17):1460-1469. doi:10.1200/JCO.18.02459<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/binimetinib-drug-information/abstract-text/30892987/pubmed" id="30892987" target="_blank">30892987</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 118324 Version 74.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
